Glenn Tate

This profile gathers the share dealings of Glenn Tate in Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.). The record holds 10 filings, for trades running from 16 October 2018 to 24 December 2021.

The open-market record is one-sided, with 7 purchases worth €29k and not one sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 2 option exercises. 2021 to date brings 6 purchases and no sales.

A typical purchase (the median) is worth €2,854. No cluster: in 6 purchases, no other insider of the company bought within 30 days.

On 29 December 2021 came the latest disclosure, an option exercise in Medexus Pharmaceuticals Inc. (formerly Pediapharm Inc.). The most recent open-market purchase was published on 19 August 2021, 1,895 days ago. The median gap between a trade and its publication by SEDI is 2 days. Until a filing is published, the market cannot know about the trade. This summary is built from SEDI disclosures alone and does not predict where the share price will go.